# Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

> **NCT03398434** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** MAA868
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT03398434
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-16
- **Primary completion:** 2019-11-28
- **Final completion:** 2020-01-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial cancelled before First Patient First Visit (no patient enrolled)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03398434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03398434, "Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03398434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*